Auto-Injectors Market Analysis, Drivers, Growth Rate, Specifications & Forecast

Auto-Injectors Market

The global auto-injectors market is likely to grow significantly during the forecast period, due to increasing prevalence of anaphylaxis, increasing cases with multiple sclerosis, rising geriatric population and high production of biologics. Additionally, increasing healthcare spending and various beneficial features of auto-injectors also contribute to the growth of the overall market. However, high cost of auto-injectors and stringent regulatory requirements are some of the key factors restraining the growth of global auto-injectors market.

Explore Report Sample at:

The prefilled auto-injectors is the larger product category in the global auto-injectors market, primarily due to increasing availability of user friendly prefilled auto-injectors in disposable form. Based on manufacturing design, standardized auto-injector was the larger contributor to the global auto-injectors market in comparison to customized auto-injector in 2016. Anaphylaxis was the largest application for auto-injectors, followed by multiple sclerosis, rheumatoid arthritis and other diseases, in 2016. According to World Allergy Organization (WAO), the prevalence of anaphylaxis ranged from 2% of the population in the US, to 0.1% of the population in Korea, and 0.6% to 1% of the population in Australia.

Globally, the increasing demand for biologics has been playing a key role in the growth of the auto-injectors market. The rapidly increasing burden of anaphylaxis, multiple sclerosis, rheumatoid arthritis and other diseases further compels government organizations and healthcare providers to provide improved facilities for effective disease treatment, leading to rising number of launches of technologically advanced products, globally.

Explore Report Description at:

Key companies in the auto-injectors market is collaborating to offer advanced auto-injectors. In March 2017, Mylan N.V. entered in a global settlement and license agreement with Genentech Inc and Roche Holding AG in relation to patents for Herceptin (trastuzumab), which provides Mylan N.V. with global licenses for its trastuzumab product. This is expected to help Mylan N.V. to commercialize trastuzumab globally, except in Japan, Brazil and Mexico.

Some of the key players operating in the global auto-injectors market include Mylan N.V., Antares Pharma Inc., Becton, Dickinson & Co., Eli Lilly and Company, Pfizer, Inc., Bayer AG, Novartis International AG, Bristol-Myer Squibb, Novartis AG, Amgen Inc. and Biogen Inc.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s